Investigators Discuss the Role of Novel Treatment Approaches in the Care of Patients with Follicular Lymphoma and Diffuse Large B-Cell Lymphoma — Symposium Video Proceedings

Faculty

TARGET AUDIENCE
This program is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of follicular lymphoma and diffuse large B-cell lymphoma.

LEARNING OBJECTIVES

• Identify patients with newly diagnosed and relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) for whom CD79b-targeted therapy would be appropriate.
• Develop an understanding of published clinical research findings with CD19-targeted monoclonal antibodies in combination with immunomodulatory agents for DLBCL and follicular lymphoma (FL), and use this information in patient-education discussions.
• Appraise available research findings with and the current clinical role of CD19-targeted antibody-drug conjugates for patients with R/R DLBCL and FL.
• Understand the biological rationale for, available research findings with and current clinical role of CD30-targeted antibody-drug conjugate-based therapy for patients with R/R DLBCL.
• Consider published and emerging research data with and the current clinical role of CD20 x CD3 bispecific antibodies for patients with R/R DLBCL and FL.
• Implement a plan of care to recognize and manage side effects and toxicities associated with novel therapies commonly used in the care of patients with DLBCL and FL.
• Recall new data with agents and strategies currently under investigation for DLBCL and FL, and discuss ongoing trial opportunities with eligible patients.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Video Program: Research To Practice designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
Successful completion of these CME activities, which includes participation in the evaluation components and post-tests, enables the participant to earn up to 2.25 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, these programs have been specifically designed for the following ABIM specialties: medical oncology and hematology.

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

HOW TO USE THIS CE ACTIVITY
Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/ASHFLDLBCL25/Video/CME.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Nancy L Bartlett, MD
Professor of Medicine
Koman Chair in Medical Oncology
Washington University School of Medicine
St Louis, Missouri

Advisory Committees: AbbVie Inc, Genentech, a member of the Roche Group, Genmab US Inc, Kite, A Gilead Company, Pfizer Inc, Seagen Inc; Contracted Research: AbbVie Inc, ADC Therapeutics, Autolus, Bristol Myers Squibb, Celgene Corporation, Forty Seven Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Kite, A Gilead Company, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Seagen Inc, Takeda Pharmaceuticals USA Inc.

John P Leonard, MD
Laura and Isaac Perlmutter Professor of Hematology and Medical Oncology
Director, Division of Hematology and Medical Oncology
Director, Center for Blood Cancers
Senior Advisor to the Dean/CEO and Chief Clinical Officer for Enterprise Cancer Strategy and Operations
Interim Director, Laura and Isaac Perlmutter Cancer Center
NYU Grossman School of Medicine
NYU Langone Health
New York, New York

Consulting Agreements: AstraZeneca Pharmaceuticals LP, BeOne, Caribou Biosciences Inc, Foresight Diagnostics, Genentech, a member of the Roche Group, Ipsen Biopharmaceuticals Inc, Kyowa Kirin Co Ltd, Novartis, Ono Pharmaceutical Co Ltd, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sail Biomedicines, Treeline Biosciences.

Matthew Matasar, MD
Chief, Division of Blood Disorders
Rutgers Cancer Institute
Hematologist/Oncologist
Professor
Rutgers Robert Wood Johnson Medical School
New Brunswick, New Jersey

Advisory Committees: Allogene Therapeutics, Arvinas, Bristol Myers Squibb, Genentech, a member of the Roche Group, Genmab US Inc, Merck; Consulting Agreements: AbbVie Inc, Genentech, a member of the Roche Group, Novartis, Pfizer Inc, Roche Laboratories Inc; Contracted Research: Genentech, a member of the Roche Group, Janssen Biotech Inc, Pfizer Inc, Roche Laboratories Inc; Honoraria and Stipends: ADC Therapeutics, AstraZeneca Pharmaceuticals LP, Ipsen Biopharmaceuticals Inc, Kite, A Gilead Company, Regeneron Pharmaceuticals Inc; Stock Ownership — Public Companies: Merck.

Loretta J Nastoupil, MD
Oncologist
Southwest Oncology
CommonSpirit Mercy Hospital
Durango, Colorado

Advisory Committees: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Genmab US Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Kite, A Gilead Company, Merck, Novartis, Regeneron Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc; Consulting Agreements: Genentech, a member of the Roche Group; Contracted Research: BeOne, Bristol Myers Squibb, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc, Kite, A Gilead Company, Merck, Novartis, Takeda Pharmaceuticals USA Inc; Data and Safety Monitoring Boards/Committees: Genentech, a member of the Roche Group.

Professor Pier Luigi Zinzani
Professor of Hematology
Alma Mater Studiorum — University of Bologna
Head, “Seràgnoli” Institute of Hematology
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Department of Medical and Surgical Sciences
Bologna University School of Medicine
Bologna, Italy

Advisory Committees: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, Gilead Sciences Inc, Incyte Corporation, Janssen Biotech Inc, Kyowa Kirin Co Ltd, Novartis, Recordati, Roche Laboratories Inc, Sobi, Takeda; Speakers Bureaus: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, Gilead Sciences Inc, Incyte Corporation, Janssen Biotech Inc, Kyowa Kirin Co Ltd, Merck, Novartis, Recordati, Roche Laboratories Inc, Sobi, Takeda.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

These activities are supported by educational grants from ADC Therapeutics, Genentech, a member of the Roche Group, Incyte Corporation, and Pfizer Inc.

Release date: January 2026
Expiration date: January 2027

After completing the post-test, learners may download and review the answers here in order to identify further areas of study.

Dr Matasar

Davies JR et al. Comparison of MHG and DZsig reveals shared biology and a core overlap group with inferior prognosis in DLBCL. Blood Adv 2023;7(20):6156-62. Research Letter

Jerkeman M et al. Initial safety data from the phase 3 POLAR BEAR trial in elderly or frail patients with diffuse large cell lymphoma, comparing R-pola-mini-CHP and R-mini-CHOP. European Hematology Association (EHA) 2023;Abstract S227.

Morschhauser F et al. Deciphering the clinical benefit of Pola-R-CHP versus R-CHOP in different genetic subtypes beyond cell of origin in the POLARIX study. ASH 2023;Abstract 3000.

Palmer AC et al. Cell-of-origin subtypes and therapeutic benefit from polatuzumab vedotin. N Engl J Med 2023;389(8):764-6. Correspondence

Sehn LH et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2020;38(2):155-65. Abstract

Tilly H et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med 2022 ;386(4):351-63. Abstract

Trnĕný M et al. Analysis of peripheral neuropathy in the POLARIX study using clinician- and patient-reported outcomes. Blood Adv 2025;9(13):3263-7. Research Letter

Wright GW et al. A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications. Cancer Cell 2020;37(4):551-68. Abstract

Dr Leonard

Cheson BD et al. Diffuse large B-cell lymphoma: New targets and novel therapies. Blood Cancer J 2021;11(4):68. Abstract

Duell J et al. Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: Final 5-year efficacy and safety findings in the phase II L-MIND study. Haematologica 2024;109(2):553-66. Abstract

Meisel A et al. Tafasitamab and lenalidomide as second-line treatment in an elderly patient with a primary refractory double-hit diffuse large B-cell lymphoma. healthbook TIMES Onco Hema 2025;23(1):151-58. Abstract

Nowakowski GS et al. First-Mind: Final analysis from a phase Ib, open-label, randomized study to assess safety of tafasitamab or tafasitamab + lenalidomide in addition to R-CHOP in patients with newly diagnosed diffuse large B-cell lymphoma. ASH 2022;Abstract 1619.

Sehn LH et al. Outcomes from the phase 3 inMIND study of tafasitamab (TAFA) plus lenalidomide (LEN) and rituximab (R) for patients with relapsed/refractory follicular lymphoma (R/R FL). International Conference on Malignant Lymphoma (ICML) 2025;Abstract 28.

Sehn LH et al. Tafasitamab plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma: Results from a phase 3 study (inMIND). ASH 2024;Abstract LBA-1.

Vitolo U et al. frontMIND: A phase III, randomized, double-blind study of tafasitamab + lenalidomide + R-CHOP versus R-CHOP alone for newly diagnosed high-intermediate and high-risk diffuse large B-cell lymphoma. ASCO 2022;Abstract TPS7590.

Volgina A et al. CD19 expression persists in diffuse large B-cell lymphoma patient biopsies after treatment with tafasitamab. EHA 2024;Abstract P1234.

Prof Zinzani

Alderuccio JP et al. Initial results from LOTIS-7: A phase 1b study of loncastuximab tesirine plus glofitamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). ICML 2025;Abstract 78.

Alderuccio JP et al. Loncastuximab tesirine with rituximab in patients with relapsed or refractory follicular lymphoma: A single-centre, single-arm, phase 2 trial. Lancet Haematol 2025;12(1):e23-34. Abstract

Bartlett NL et al. Brentuximab vedotin combination for relapsed diffuse large B-cell lymphoma. J Clin Oncol 2025;43(9):1061-72. Abstract

Hamadani M et al. Clinical outcomes of older and younger patients treated with loncastuximab tesirine in the LOTIS-2 clinical trial. Blood Adv 2024;8(1):93-8. Research Letter

Kim JA et al. Brentuximab vedotin in combination with lenalidomide and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: Results from the phase 3 ECHELON-3 study. ASCO 2024;Abstract LBA7005.

Matasar M et al. Polatuzumab vedotin, rituximab, gemcitabine and oxaliplatin (POLA-R-GEMOX) for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Results from the randomized phase III POLARGO trial. EHA 2025;Abstract S101.

Dr Bartlett

Abramson JS et al. Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): A global phase 3, randomised, open-label trial. Lancet 2024;404(10466):1940-54. Abstract

Bartlett NL et al. Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma. Blood Adv 2023;7(17):4926-35. Abstract

Brody JD et al. Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: Results from the EPCORE NHL-2 trial. Blood 2025;145(15):1621-31. Abstract

Budde LE et al. Mosunetuzumab plus polatuzumab vedotin in transplant-ineligible refractory/relapsed large B-cell lymphoma: Primary results of the phase III SUNMO trial. J Clin Oncol 2025;43(36):3799-811. Abstract

Dickinson MJ et al. Fixed-duration glofitamab monotherapy continues to demonstrate durable responses in patients with relapsed or refractory large B-cell lymphoma: 3-year follow-up from a pivotal phase II study. ASH 2024;Abstract 865.

Dickinson MJ et al. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 2022;387(24):2220-31. Abstract

Falchi L et al. Fixed-duration epcoritamab + R-CHOP in patients with newly diagnosed DLBCL and high IPI scores (3–5) led to sustained remissions and disease-free survival beyond 3 years: Results from the EPCORE NHL-2 trial. ASH 2025;Abstract 1955.

Falchi L et al. Bispecific antibodies for the treatment of B-cell lymphoma: Promises, unknowns, and opportunities. Blood 2023;141(5):467-80. Abstract

Hutchings M et al. Efficacy and safety of glofitamab plus polatuzumab vedotin in relapsed/refractory large B-cell lymphoma including high-grade B-cell lymphoma: Results from a phase Ib/II trial. J Clin Oncol 2025;43(36):3788-98. Abstract

Kim WS et al. Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: Primary efficacy and safety analysis in phase 2 ELM-2 trial. Nat Cancer 2025;6(3):528-39. Abstract

Lavie D et al. Durable efficacy with fixed-duration epcoritamab + polatuzumab, vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (POLA-R-CHP) for 1L DLBCL (EPCORE NHL-5). ICML 2025;Abstract 282.

Li T et al. Optimal dosing regimen for epcoritamab, a subcutaneous bispecific antibody, in relapsed or refractory large B-cell lymphoma. Clin Pharmacol Ther 2025;117(5):1437-50. Abstract

Minson A et al. Glofitamab combined with Pola-R-CHP or R-CHOP as first therapy in younger patients with high-risk large B-cell lymphoma: Results from the COALITION study. J Clin Oncol 2025;43(23):2595-605. Abstract

Minson AG, Dickinson MJ. New bispecific antibodies in diffuse large B-cell lymphoma. Haematologica 2025 ;110(7):1483-99. Abstract

Thieblemont C et al. Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial. Leukemia 2024;38(12):2653-62. Abstract

Westin J et al. Mosunetuzumab plus Pola-CHP compared with Pola-R-CHP in previously untreated DLBCL: Final results from a phase 2 study. Blood Adv 2025;9(10):2461-72. Abstract

Dr Nastoupil

Blair HA. Odronextamab: First approval. Drugs 2024;84(12):1651-8. Abstract

Budde LE et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: A single-arm, multicentre, phase 2 study. Lancet Oncol 2022;23(8):1055-65. Abstract

Devata S et al. AZD0486, a novel CD19XCD3 T-cell engager, shows durable responses in patients with relapsed/refractory follicular lymphoma: Update on efficacy and safety. EHA 2024;Abstract P1131.

Flinn IW et al. Fixed duration subcutaneous (SC) mosunetuzumab (Mosun) in patients with previously untreated high-tumor burden follicular lymphoma (FL): Interim results from the phase II MorningSun study. ASCO 2025;Abstract 7014.

Karimi Y et al. Effect of follow-up time on the ability of subcutaneous epcoritamab to induce deep and durable complete remissions in patients with relapsed/refractory large B-cell lymphoma: Updated results from the pivotal EPCORE NHL-1 trial. ASCO 2023;Abstract 7525.

Kim TM et al. Efficacy and safety of odronextamab in relapsed/refractory marginal zone lymphoma (R/R MZL): Data from the R/R MZL cohort in the ELM-2 study. ASH 2024;Abstract 862.

Linton KM et al. Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): A phase 2 cohort of a single-arm, multicentre study. Lancet Haematol 2024;11(8):e593-605. Abstract

Luminari S et al. Long-term efficacy and survival outcomes with odronextamab for patients (pts) with relapsed/refractory follicular lymphoma (R/R FL): 2-year follow-up from the phase 2 ELM-2 study. EHA 2025;Abstract S235.

Nastoupil LJ et al. CELESTIMO: A phase III trial evaluating the efficacy and safety of mosunetuzumab plus lenalidomide versus rituximab plus lenalidomide in patients with relapsed or refractory follicular lymphoma who have received ≥ 1 line of systemic therapy. ASCO 2022;Abstract TPS7588.

Phillips T et al. Glofitamab monotherapy in patients with heavily pretreated relapsed or refractory mantle cell lymphoma: Updated analysis from a phase I/II study. EHA 2024;Abstract S231.

Phillips TJ et al. GLOBRYTE: A phase III, open-label, multicenter, randomized trial evaluating glofitamab monotherapy in patients with relapsed or refractory mantle cell lymphoma. ASH 2023;Abstract 3052.

Sehn LH et al. Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies. Blood 2025;145(7):708-19. Abstract

Thieblemont C et al. Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: Dose expansion in a phase I/II trial. J Clin Oncol 2023;41(12):2238-47. Abstract

Thiruvengadam S et al. Phase II investigator-initiated trial of epcoritamab-lenalidomide in treatment naïve follicular lymphoma. EHA 2025;Abstract PS1892.

Wang ML et al. Fixed duration mosunetuzumab plus polatuzumab vedotin has promising efficacy and a manageable safety profile in patients with BTKi relapsed/refractory mantle cell lymphoma: Initial results from a phase Ib/II study. ASH 2023;Abstract 734.